An observational study in Uveitis, sponsored by IRCCS Ospedale San Raffaele. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by IRCCS Ospedale San Raffaele · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Uveitis is a group of eye diseases that cause inflammation and may lead to vision loss. The biological processes responsible for these diseases are not fully understood, particularly in rare forms of uveitis.
The purpose of UVEOMICS is to collect and store biological samples and clinical information from adults with infectious or non-infectious uveitis, including rare inflammatory eye diseases known as white dot syndromes. Researchers will study these samples to better understand the causes of eye inflammation and identify biological markers that may help improve diagnosis, monitor disease activity, predict relapses, and guide future treatments.
The study plans to enroll approximately 2,000 adults, including 1,500 patients with uveitis and 500 individuals undergoing cataract surgery who will serve as a comparison group.
Participants may provide blood samples and small samples of fluid from inside the eye (aqueous humor or vitreous fluid), when appropriate. Samples and clinical information may be collected at different stages of the disease and during follow-up visits. Biological samples will be stored for future research and analyzed together with clinical findings and eye imaging results.
This is an observational study. Participation will not change the medical care or treatment participants receive.
300 studies on the registry are indexed under Uveitis; 32 are open to participants now.
This study's planned enrollment of 200 is above the median of 107 across 104 observational studies indexed under Uveitis.
Browse Uveitis studies →IRCCS Ospedale San Raffaele is the lead sponsor of 37 studies on the registry; 29 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will include approximately 2,000 adults recruited at the IRCCS Ospedale San Raffaele in Milan, Italy.
Approximately 1,500 participants will be patients diagnosed with infectious or non-infectious uveitis, including rare inflammatory eye diseases known as white dot syndromes. An additional 500 participants will be adults without uveitis undergoing elective cataract surgery, who will serve as a comparison group.
Participants will be recruited consecutively during routine outpatient visits, hospital admissions, and diagnostic or surgical procedures. Patients with uveitis may provide biological samples at different stages of their disease, including active inflammation, remission, and relapse.
Recruitment will be non-probabilistic and will include eligible adults regardless of sex or ethnicity who provide written informed consent.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For patients with uveitis:
Age 18 years or older.
Clinical diagnosis of infectious or non-infectious uveitis (anterior, intermediate, posterior, or panuveitis), including rare white dot syndromes such as multiple evanescent white dot syndrome (MEWDS), punctate inner choroidopathy (PIC), idiopathic multifocal choroiditis (iMFC), acute zonal occult outer retinopathy (AZOOR), acute posterior multifocal placoid pigment epitheliopathy (APMPPE), and serpiginoid chorioretinitis.
Ability to understand and provide written .
Willingness to provide biological samples (blood and/or aqueous humor and/or vitreous humor, when clinically indicated) and associated clinical information.
Exclusion Criteria:
Age younger than 18 years.
Severe systemic conditions that make biological sample collection unsafe, such as uncontrolled diabetes, systemic infections, or inability to be seated at the slit lamp.
Inability to provide valid .
Refusal to participate or withdrawal of informed consent.
Pregnancy or breastfeeding if these conditions contraindicate the planned biological sampling.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
uveitis patients
Number of biological samples collected and stored in the UVEOMICS biobank
The total number of biological samples (blood, aqueous humor, and vitreous humor, when clinically available) collected, processed, and stored from enrolled participants for future immunological and molecular research. Samples will be linked to clinical and imaging data and may be collected at different stages of disease activity.
Time frame: Throughout the study period (approximately 6 years).
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2030, 48 months later.
Of 32 observational studies under Uveitis, half reached primary completion within 77 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 143. This study's planned 48 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Ospedale San Raffaele